Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

A legfontosabb adatok

Ki végzi
Crinetics Pharmaceuticals Inc.
Hol
Ann Arbor, Cleveland, East Providence, Minneapolis, Morehead City, Pasadena, Philadelphia és St Louis (Egyesült Államok)Mind a 8 helyszín megnézéseMég 6 másik országban, 17 helyszínen
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
38 fő vett részt
Kezdés
2023. júl. 3.
Befejezés
2025. aug. 22.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • atumelnant (CRN04894)
A regiszteradat frissítve
2026. szeptember 10.

Ki vehet részt

Életkor
16 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female participants ≥18 to 75 years of age at the time of signing the Informed Consent Form (ICF). Participants ≥16 years of age may be included in sites located in the United States
  • Classic 21-hydroxylase deficiency
  • On a stable regimen of glucocorticoid replacement (eg, hydrocortisone, prednisolone, prednisone, methylprednisolone)
  • Compliance with glucocorticoid replacement and mineralocorticoid replacement (if applicable) regimen during the Screening Period
  • Minimum total daily dose of ≥15 mg hydrocortisone (or equivalent). For Cohort 4, a mean daily dose of ≥11 mg/m²/day of hydrocortisone or hydrocortisone equivalents will be used for inclusion
  • If on estrogen therapy (any route), dose must be stable for at least 3 months prior to Screening

Ki nem vehet részt

  • Dexamethasone use within 30 days of Screening for Cohorts 1-3. In Cohort 4, dexamethasone is permitted
  • History of major surgery/surgical therapy for any cause within 4 weeks prior to Screening
  • Diabetes mellitus treated with insulin for less than 6 weeks prior to Screening, or with change in total daily insulin dose by >15% within 6 weeks prior to Screening
  • Participants with hypothyroidism who are not receiving adequate hormone replacement therapy based on thyroid hormone levels measured at the time of Screening
  • History of unstable angina or acute myocardial infarction within 12 weeks prior to Screening or other clinically significant cardiac disease at the time of Screening
  • Use of antiandrogen therapy in the past 3 months (eg, spironolactone, finasteride, cyproterone acetate, flutamide)
  • Use of testosterone, androgen-containing supplements, aromatase inhibitors, or growth hormone
  • History of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
  • Clinically significant unstable medical condition or chronic disease other than CAH
  • History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ
  • Known history of illicit drug or alcohol abuse within the last year
  • Poorly controlled diabetes mellitus defined as having a hemoglobin A1c (HbA1c) ≥8.5%(≥69 mmol/mL), or estimated HbA1c based on fructosamine if HbA1c is not evaluable (eg, due to hemoglobinopathies)
  • Diagnosis of any other form of CAH other than classic 21-hydroxylase deficiency
  • Night shift workers or any other reason for abnormal sleep/wake cycles
  • Pregnant or lactating

Helyszínek itt: Egyesült Államok

Még 6 másik országban, 17 helyszínen

  • Ann Arbor, MichiganHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • East Providence, Rhode IslandHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • Morehead City, North CarolinaHospital not named in the registry
  • Pasadena, CaliforniaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.

A vizsgálat csoportja

  • Sequential DoseA vizsgált kezelés

    Sequential, open-label, 12-week fixed-dose cohorts.

    Kezelés: atumelnant (CRN04894)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
A regiszteradat frissítve
2026. szeptember 10.